RxDoctor Payments DataLook up a doctor →

Shellie Hardcastle, APRN

Family · Bowling Green, KYNPI 1033111901

Payments from drug & device makers

$14,969in general payments, 2019–2025

Across 633 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Pfizer$803
  • Seagen Inc.$759
  • Daiichi Sankyo Inc.$742
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis73$2,377
AstraZeneca(2 entities)50$1,418
Johnson & Johnson43$1,005
Pfizer53$803
Seagen Inc.20$759
Daiichi Sankyo Inc.30$742
Bristol Myers Squibb30$561
E.r. Squibb & Sons, L.L.C.28$531
Merck26$449
Genentech USA, Inc.19$399
Sanofi13$323
Gilead13$312
Exelixis Inc.13$298
Regeneron Healthcare Solutions, Inc.11$282
AbbVie9$280
Incyte Corporation10$248
Pharmacyclics LLC, An Abbvie Company10$234
Amgen11$222
Beigene USA, Inc.3$184
Coherus Oncology, Inc.9$173
Lilly USA, LLC9$166
Eisai Inc.8$163
Angiodynamics, Inc.2$141
AVEO Pharmaceuticals, Inc.6$140
Progenics Pharmaceuticals, Inc.2$139
Taiho Oncology, Inc.6$131
Beone Medicines USA, Inc.3$126
Astellas Pharma US Inc6$124
Takeda Pharmaceuticals U.S.A., Inc.5$111
Stemline Therapeutics Inc.5$105
Genmab U.S., Inc.4$97
Array Biopharma Inc9$94
Bayer6$94
EMD Serono, Inc.3$91
ADC Therapeutics America, Inc.5$91
Pharmacosmos Therapeutics Inc.5$87
Boehringer Ingelheim4$86
Karyopharm Therapeutics Inc.5$85
Ipsen Biopharmaceuticals, Inc5$81
Rigel Pharmaceuticals, Inc.4$79
Pharmaessentia USA Corporation4$78
Geron Corporation2$74
Sobi, Inc3$62
Kyowa Kirin, Inc.3$60
Blueprint Medicines Corporation3$60
Morphosys, US Inc.3$57
Azurity Pharmaceuticals, Inc.2$57
Tersera Therapeutics LLC2$56
Global Blood Therapeutics, Inc.3$52
Puma Biotechnology, Inc.3$47
G1 Therapeutics, Inc.2$44
Mirati Therapeutics, Inc.2$41
TG Therapeutics, Inc.2$40
GSK2$38
Myovant Sciences Inc.2$31
Apellis Pharmaceuticals, Inc.2$29
Novocure Inc.1$24
Dova Pharmaceuticals1$23
Alnylam Pharmaceuticals Inc.1$22
Accord Healthcare, Inc.1$21

How this compares

$14,969 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky →

Medicare billing

Part B allowed, 2024
$8,332
Medicare patients
71
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Bowling Green

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →